5HT1 receptor agonists and a cox-2 inhibitor or NSAIDs for the treatment of migrana

• 1. COX-2抑制剂用于治疗不携带与肝脏毒性相关的HLA等位基因的患者中COX-2依赖性疾病的用途 [P] . 中国专利： CN102197144A . 2011-09-21
• 2. 用于治疗肿瘤形成的放疗与COX－2抑制剂的联合治疗 [P] . 中国专利： CN1398189A . 2003-02-19
• 3. 5HT1 receptor agonists and a cox-2 inhibitor or NSAIDs for the treatment of migrana [P] . PE01232001A1 . 2001-02-03

  机译： 5HT1受体激动剂和cox-2抑制剂或NSAIDs用于治疗偏头痛

• 4. Composition of a 5HT1 receptor agonist and a cox-2 inhibitor for the treatment of migrana [P] . PE01282001A1 . 2001-02-28

  机译： 用于治疗偏头痛的5HT1受体激动剂和cox-2抑制剂的组合物

• 5. Combination of a 5HT1 receptor agonist, Caffeine, a cox-2 inhibitor or a non steroidal anti-inflammatory Drug and its use for the treatment of migrana [P] . PE03862001A1 . 2001-04-05

  机译： 5HT1受体激动剂，咖啡因，cox-2抑制剂或非甾体抗炎药的组合及其在治疗偏头痛中的用途

• 1. The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer’s disease：agonists or antagonists? [J] . Rubina Marzagalli, Alessandro Castorina 中国神经再生研究（英文版） . 2015,第002期
• 2. GI and CardiovascularProfilesof New NSAIDs: Selective COX-2 Inhibitors andNO-NSAIDs [C] . Marcelo N. Muscara, Webb McKnight, Michael Dicay, International Stereotactic Radiosurgery Society . 2000
• 3. Serotonin Receptor Signaling Following Selective Serotonin Reuptake Inhibitor Treatment or: How I Learned to Stop Worrying and Love the Agonist. [D] . Van Dyke, Adam M. 2016
• 4. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018
• 5. PAO1: COST-EFFECTIVENESS ANALYSIS OF NSAIDS VS COX-2 SPECIFIC INHIBITORS AND NSAIDS WITH CO-TREATMENTS TO PREVENT Gl TOXICITY IN THE TREATMENT OF RA [O] . Yun HR, Corzillius M, Kim SY, 2000

• 1. Review on the Effect of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Non-Alcoholic Fatty Liver Disease [J] . Chao-lin LI ,Lu-jie ZHAO ,Xin-li ZHOU . 华中科技大学学报（医学）（英德文版） . 2015,第003期
• 2. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? [J] . Maja Cigrovski Berkovic ,Ines Bilic-Curcic ,Tomislav Bozek . 世界糖尿病杂志：英文版（电子版） . 2020,第11期
• 3. Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and metaanalysis of randomized trials [J] . Hasan M Shihab ,Tokunbo Akande ,Kacie Armstrong . 世界荟萃分析杂志 . 2015,第6期
• 4. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives [J] . Michael Hpfner ,Detlef Schuppan ,Hans Scherübl . 世界胃肠病学杂志：英文版 . 2008,第16期
• 5. 五七散对NSAIDs相关性胃病大鼠胃粘膜COX-2、TNF-ɑ表达的影响 [C] . 陈涤平 ,郑亮 ,王培 . 世界中医药学会联合会消化病专业委员会第六届消化病国际学术大会 . 2015
• 6. 基于片段的COX-2/5-LOX双效抑制剂类NSAIDs设计的研究 [A] . 任小姗 . 2014